Diligence memo · auto-generated · as of July 2, 2026
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Crinetics Pharmaceuticals, Inc. operates in Biotechnology, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Crinetics Pharmaceuticals, Inc. has raised $428M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $350M on 2024-03-01.
Most recent recorded round closed around 2024-03-01.
Valuation (modeled)modeled
Provath models Crinetics Pharmaceuticals, Inc. at approximately $4.3B (range $1.6B–$6.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.13× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 50 months.
Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 5.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, 2seventy bio, Inc., Gio World Health (Europe) Sa, GIO World Health (Europe) Ltd.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.